Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Comparing the Radial Extracorporeal Shock Waves and Botulinum Toxin Injection for Spasticity

First Posted Date
2017-04-27
Last Posted Date
2018-08-20
Lead Sponsor
Mackay Memorial Hospital
Target Recruit Count
42
Registration Number
NCT03131791
Locations
🇨🇳

Mackay Memorial Hospital, Taipei, Taiwan

Muscle Elastography in Spastic Cerebral Palsy

First Posted Date
2017-04-13
Last Posted Date
2022-04-21
Lead Sponsor
Hospital for Special Surgery, New York
Target Recruit Count
16
Registration Number
NCT03112434
Locations
🇺🇸

Hospital for Special Surgery, New York, New York, United States

Botulinum Toxin for Erectile Dysfunction

First Posted Date
2017-04-06
Last Posted Date
2020-01-07
Lead Sponsor
Cairo University
Target Recruit Count
70
Registration Number
NCT03102762
Locations
🇪🇬

Department of Andrology, Cairo University, Cairo, Egypt

A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

First Posted Date
2017-03-13
Last Posted Date
2019-01-23
Lead Sponsor
Daniel Lieberman
Target Recruit Count
4
Registration Number
NCT03078270
Locations
🇺🇸

GW University Medical Faculty Associated, Washington, District of Columbia, United States

Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population

First Posted Date
2017-02-16
Last Posted Date
2023-10-18
Lead Sponsor
University of California, Irvine
Target Recruit Count
17
Registration Number
NCT03055767
Locations
🇺🇸

UC Irvine Medical Center, Orange, California, United States

🇺🇸

Gottschalk Medical Plaza, Irvine, California, United States

Fractional Micro-Needle Radiofrequency and I Botulinum Toxin A for Primary Axillary Hyperhidrosis

First Posted Date
2017-02-15
Last Posted Date
2017-02-16
Lead Sponsor
Mae Fah Luang University Hospital
Target Recruit Count
40
Registration Number
NCT03054480

Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot

First Posted Date
2017-02-06
Last Posted Date
2017-10-20
Lead Sponsor
Parc de Salut Mar
Target Recruit Count
20
Registration Number
NCT03044080
Locations
🇪🇸

Hospital de l'Esperança, Barcelona, Spain

Effect of Type-A Botulinum Toxin in the Post-radiosurgical Neck Contractures

First Posted Date
2016-12-08
Last Posted Date
2017-05-25
Lead Sponsor
Hopital Foch
Target Recruit Count
14
Registration Number
NCT02986880
Locations
🇫🇷

Hopital Foch, Suresnes, France

Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm

Phase 2
Completed
Conditions
Interventions
First Posted Date
2016-10-28
Last Posted Date
2019-06-26
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
234
Registration Number
NCT02947815
Locations
🇰🇷

the catholic university of korea, Seoul ST. Mary's Hospital., Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath